Literature DB >> 12771540

How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin.

Brigitte Meyer1, Salwa Ahmed el Gendy, Georg Delle Karth, Gottfried J Locker, Gottfried Heinz, Walter Jaeger, Florian Thalhammer.   

Abstract

BACKGROUND: Flucloxacillin is an important antimicrobial drug in the treatment of infections with Staphylococcus aureus and therefore is often used in staphylococcal infections. Furthermore, flucloxacillin has a high protein binding rate as for example ceftriaxone or teicoplanin--drugs which have formerly been characterized as not being dialyzable.
METHODS: The pharmacokinetic parameters of 4.0 g flucloxacillin every 8 h were examined in 10 intensive care patients during continuous venovenous hemofiltration (CVVH) using a polyamide capillary hemofilter. In addition, the difficulty of calculating the hemofiltration clearance of a highly protein-bound drug is described.
RESULTS: Flucloxacillin serum levels were significantly lowered (56.9 +/- 24.0%) even though only 15% of the drug was detected in the ultrafiltrate. Elimination half-life, total body clearance and sieving coefficient were 4.9 +/- 0.7 h, 117.2 +/- 79.1 ml/min and 0.21 +/- 0.09, respectively. These discrepancies can be explained by the high protein binding of flucloxacillin, the adsorbing property of polyamide and the equation in order to calculate hemofiltration clearance. The unbound fraction of a 4.0 g flucloxacillin dosage facilitates time above the minimum inhibitory concentration (T > MIC) of 60% only for strains up to a minimum inhibitory concentration (MIC) of 0.5 mg/l.
CONCLUSION: Based on the data of this study, we conclude that intensive care patients with staphylococcal infections on CVVH should be treated with 4.0 g flucloxacillin every 8 h which was safe and well tolerated. Moreover, further studies with highly protein-bound drugs are recommended to check the classical 'hemodialysis' equation as the standard equation in calculating the CVVH clearance of highly protein-bound drugs. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771540     DOI: 10.1159/000070997

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  14 in total

1.  Adsorption of amikacin, a significant mechanism of elimination by hemofiltration.

Authors:  Qi Tian; Charles D Gomersall; Margaret Ip; Perpetua E Tan; Gavin M Joynt; Gordon Y S Choi
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

Review 2.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  [Pharmacokinetic and pharmacodynamic aspects in antibiotic treatment].

Authors:  R Bellmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-03-20       Impact factor: 0.840

4.  Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing.

Authors:  Catherine S C Bouman; Hendrikus J M van Kan; Richard P Koopmans; Johanna C Korevaar; Marcus J Schultz; Margreeth B Vroom
Journal:  Intensive Care Med       Date:  2006-10-17       Impact factor: 17.440

5.  Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration.

Authors:  Matthias G Vossen; Klaus-Bernhard Gattringer; Walter Jäger; Stefanie Kraff; Florian Thalhammer
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

6.  Doripenem Treatment during Continuous Renal Replacement Therapy.

Authors:  M G Vossen; J M Wenisch; A Maier-Salamon; A Fritsch; K Saria; C Zuba; S Jilch; R Lemmerer; M Unger; U Jaehde; W Jäger; F Thalhammer
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

7.  Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy.

Authors:  M G Vossen; L Ehmann; S Pferschy; A Maier-Salamon; M Haidinger; C Weiser; J M Wenisch; K Saria; C Kajahn; S Jilch; R Lemmerer; M Bécède; M Zeitlinger; C Kloft; W Jäger; F Thalhammer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

8.  Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig-Schippers; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy.

Authors:  M Biagi; D Butler; X Tan; S Qasmieh; K Tejani; S Patel; R M Rivosecchi; M H Nguyen; C J Clancy; R K Shields; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

10.  Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.

Authors:  Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-07-28       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.